Skip to main content
رجوع
AXSM logo

Axsome Therapeutics, Inc.

جودة البيانات: 100%
AXSM
NASDAQ Healthcare Biotechnology
KWD 161.78
▲ KWD 3.03 (1.91%)
القيمة السوقية: 8.28B
نطاق اليوم
KWD 160.60 KWD 163.48
نطاق 52 أسبوعًا
KWD 86.99 KWD 191.50
حجم التداول
434,869
متوسط 50 يوم / 200 يوم
KWD 174.32 / KWD 137.24
الإغلاق السابق
KWD 158.75

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -45.2 0.2
P/B 93.7 3.0
ROE % -252.1 3.6
Net Margin % -28.7 3.8
Rev Growth 5Y % 9.9
D/E 2.7 0.2

السعر المستهدف للمحللين

Hold
KWD 222.43 +37.5%
Low: KWD 200.00 High: KWD 260.00
ربحية السهم المستقبلية
-KWD 0.82
الإيرادات المقدّرة
987.95M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 26.58
KWD 21.01 – KWD 32.01
3.26B 12
FY2029 KWD 21.20
KWD 16.76 – KWD 25.53
2.76B 8
FY2028 KWD 13.12
KWD 1.26 – KWD 22.87
2.08B 14

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-23 -KWD 0.69 -KWD 0.71 -2.3%
2025-11-03 -KWD 0.82 -KWD 0.94 -14.6%
2025-08-04 -KWD 1.00 -KWD 0.92 +8.0%
2025-05-05 -KWD 1.26 -KWD 0.80 +36.5%
2025-02-18 -KWD 1.00 -KWD 0.96 +4.0%
2024-11-12 -KWD 1.38 -KWD 1.34 +2.9%
2024-08-05 -KWD 1.30 -KWD 1.24 +4.6%
2024-05-06 -KWD 1.20 -KWD 1.09 +9.2%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Debt/Equity of 2.73 — high leverage
Negative free cash flow of -93.41M
Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)65.55%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-252.11%
ROIC-38.51%
Net Margin-28.69%
Op. Margin-26.51%

الأمان

Debt / Equity
2.73
Current Ratio1.55
Interest Coverage-25.81

التقييم

P/E Ratio
-45.18
Forward P/EN/A
P/B Ratio93.73
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 65.55% Revenue Growth (3Y) 53.61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 638.50M Net Income (TTM) -183.17M
ROE -252.11% ROA -26.55%
Gross Margin 92.56% Operating Margin -26.51%
Net Margin -28.69% Free Cash Flow (TTM) -93.41M
ROIC -38.51% FCF Growth (3Y) N/A
Safety
Debt / Equity 2.73 Current Ratio 1.55
Interest Coverage -25.81
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -45.18 Forward P/E N/A
P/B Ratio 93.73 P/S Ratio 12.96
PEG Ratio 1.29 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 8.38 Fwd Earnings Yield N/A
FCF Yield -1.13%
Market Cap 8.28B Enterprise Value 8.19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 638.50M 385.69M 270.60M 50.04M 0.0
Net Income -183.17M -287.22M -239.24M -187.13M -130.40M
EPS (Diluted) -3.68 -5.99 -5.27 -4.60 -3.47
Gross Profit 591.02M 352.39M 244.54M 44.84M 0.0
Operating Income -169.24M -280.56M -231.83M -179.80M -124.71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 689.81M 568.50M 588.24M 331.48M 87.79M
Total Liabilities 601.51M 511.48M 397.26M 221.92M 72.15M
Shareholders' Equity 88.30M 57.02M 190.98M 109.56M 15.63M
Total Debt 241.30M 192.96M 186.37M 94.68M 49.71M
Cash & Equivalents 322.93M 315.35M 386.19M 200.84M 86.47M
Current Assets 588.99M 485.06M 504.26M 245.64M 86.52M
Current Liabilities 378.84M 230.10M 138.85M 96.56M 23.07M